Promontory Therapeutics
Christina Yim, PhD has had a diverse range of work experiences. Christina began their career in 2009 as a Summer Undergraduate Researcher at the Centre for Addiction and Mental Health. In 2010, they worked as an Independent Undergraduate Researcher in Developmental Biology at the University of Toronto, followed by a role as a Clinical Pharmacology Undergraduate Researcher.
In 2011, Christina moved on to Dartmouth College, where they pursued their PhD in Chemistry. Their time at Dartmouth lasted from August 2011 to January 2017.
After completing their PhD, Christina joined Memorial Sloan Kettering Cancer Center as a Postdoctoral Research Fellow in February 2017. Christina remained in this position until July 2019.
Christina's most recent position has been at Promontory Therapeutics. Christina started at the company in August 2019 as a Director of Research and Analytics. In January 2023, they were promoted to Senior Director of Research and Development, where they currently hold the position.
Christina Yim, PhD, completed their education history as follows:
From 2007 to 2011, they attended the University of Toronto, where they pursued an Honours Bachelor of Science with Distinction in the Pharmacology Specialist Program.
Subsequently, from 2011 to 2017, Christina Yim pursued their Doctor of Philosophy (Ph.D.) degree at Dartmouth College. Their field of study during this period was Cancer Biology and Molecular Therapeutics, specifically as part of the Program in Experimental and Molecular Medicine.
Additionally, in 2005, they obtained an Associate of the Royal Conservatory (ARCT) Diploma in Piano Performance from The Royal Conservatory of Music.
Promontory Therapeutics
Promontory Therapeutics Inc. is a clinical stage pharmaceutical company developing small molecule immunotherapies. The company's lead candidate, PT-112, is a novel chemical entity under clinical development that exhibits a unique combination of properties, including immunogenic cell death as well as osteotropism that confers advantages indealing with cancers that originate in or metastasize to the bone. Clinical data generated to date across three Phase 1 studies have demonstrated single-agent anti-cancer activity and an attractive tolerability profile, and three Phase 2 studies of PT-112 are underway. The company also sponsors the ongoing clinical study of PT-112 in combination with the PD-L1 inhibitor avelumab under a collaboration agreement with Pfizer and Merck KGaA, Darmstadt, Germany (operating as EMD Serono in the US and Canada), and has an active collaborative research and development agreement (CRADA) with the NCI to conduct a Phase 2 trial utilizing PT-112 in thymic epithelial tumors.